Abstract
Glioblastomas are malignant neoplasms composed of diverse cell populations. This intratumoral diversity has an underlying architecture, with a hierarchical relationship through clonal evolution from a common ancestor. Therapies are limited by emergence of resistant subclones from this phylogenetic reservoir. To characterize this clonal ancestral origin of recurrent tumors, we determined phylogenetic relationships using whole exome sequencing of pre-treatment IDH1/2 wild-type glioblastoma specimens, matched to post-treatment autopsy samples (n = 9) and metastatic extracranial post-treatment autopsy samples (n = 3). We identified “truncal” genetic events common to the evolutionary ancestry of the initial specimen and later recurrences, thereby inferring the identity of the precursor cell population. Mutations were identified in a subset of cases in known glioblastoma genes such as NF1(n = 3), TP53(n = 4) and EGFR(n = 5). However, by phylogenetic analysis, there were no protein-coding mutations as recurrent truncal events across the majority of cases. In contrast, whole copy-loss of chromosome 10 (12 of 12 cases), copy-loss of chromosome 9p21 (11 of 12 cases) and copy-gain in chromosome 7 (10 of 12 cases) were identified as shared events in the majority of cases. Strikingly, mutations in the TERT promoter were also identified as shared events in all evaluated pairs (9 of 9). Thus, we define four truncal non-coding genomic alterations that represent early genomic events in gliomagenesis, that identify the persistent cellular reservoir from which glioblastoma recurrences emerge. Therapies to target these key early genomic events are needed. These findings offer an evolutionary explanation for why precision therapies that target protein-coding mutations lack efficacy in GBM.
Highlights
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a poor prognosis
We used a PCR-based assay followed by generation sequencing to evaluate the presence and cancer cell fraction of the TERT promoter mutation
We sequenced to high depth
Summary
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a poor prognosis. Therapies (including therapies that target specific alterations) that have shown efficacy in other cancers have failed in GBM. In the past 3 decades, only a single cytotoxic chemotherapeutic agent, temozolomide (TMZ), has been approved and widely used for GBM and this drug only modestly extends survival. Starting from a normal cell, cancers evolve via multiple rounds of mutation, selection, and expansion.[4, 5] Continued elaboration of this phylogenetic process within the growing cancer-cell population results in branched genetic variegation,[6] whereby multiple cancer subclones relate to each other in a phylogenetic tree-like fashion.[7] cancer biospecimens are substantially heterogeneous both across different anatomical regions[8,9,10,11] and within single cancer biopsies.[11,12,13,14,15]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.